Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Bowen's Disease

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Methyl aminolaevulinate photodynamic therapy (MAL-PDT) is an effective treatment for Bowen's disease (BD) of the lower extremities. Er:YAG ablative fractional laser (AFL) treatment removes the stratum corneum to increase MAL uptake and may improve efficacy. However, no studies have directly compared the efficacy of MAL-PDT with and without Er:YAG AFL in treating BD of the lower extremities in Asians.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dong-A University
• Treatments: Aminolevulinic Acid; Methyl 5-aminolevulinate

Criteria

Inclusion Criteria:

• Korean patients aged ≥ 18 years who had biopsy-confirmed BD lesions on the lower extremities

Exclusion Criteria:

• porphyria,

• known allergies to the MAL cream or lidocaine,

• pregnancy,

• lactation,

• any active systemic infectious disease,

• immunosuppressive treatment,

• personal history of malignant melanoma,

• tendency towards melasma or keloid formation,

• prior treatment of the lesions within 4 weeks, and

• any indication of poor compliance